论文部分内容阅读
目的:探讨表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变在晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)靶向治疗中的指导意义。方法:对122例既往至少接受过1次含铂类药物化疗达到稳定以上疗效的NSCLC的病理组织行EGFR基因检测,根据检测的结果把患者分为EGFR突变型口服吉非替尼组、EGFR野生型口服吉非替尼组和EGFR野生型多烯紫杉醇化疗组。对3组患者进行临床特征、病理、疗效、生存期、PS评分、不良反应及生活质量的分析。结果:女性、腺癌、吸烟者的EGFR突变率高于对应组;EGFR突变型口服吉非替尼的客观有效率、1年生存率、中位无疾病生存期、中位生存期、PS评分和生活质量优于EGFR野生型口服吉非替尼组;EGFR野生型多烯紫杉醇化疗组的客观有效率、中位无疾病生存期和中位生存期优于EGFR野生型口服吉非替尼组,但1年生存率、PS评分和生活质量无显著差异。结论:表皮生长因子受体基因突变可作为指导晚期非小细胞肺癌维持治疗的重要指标。
Objective: To investigate the significance of epidermal growth factor receptor (EGFR) gene mutation in the targeted therapy of advanced non-small cell lung cancer (NSCLC). Methods: The EGFR gene was detected in 122 pathologically confirmed NSCLC patients who had received at least one platinum-based chemotherapy. According to the results of the test, patients were divided into EGFR mutant oral gefitinib group, EGFR wild type Type gefitinib group and EGFR wild-type docetaxel chemotherapy group. The clinical features, pathology, curative effect, survival, PS score, adverse reactions and quality of life of 3 groups of patients were analyzed. Results: The EGFR mutation rate of female, adenocarcinoma and smoker was higher than that of corresponding group. The objective effective rate, 1-year survival rate, median disease-free survival, median survival and PS score of EGFR mutant oral gefitinib And quality of life better than EGFR wild-type oral gefitinib group; EGFR wild type docetaxel chemotherapy group objective efficiency, median disease-free survival and median survival was better than EGFR wild-type oral gefitinib group , But there was no significant difference in 1-year survival rate, PS score and quality of life. Conclusion: Epidermal growth factor receptor gene mutation can be used as an important indicator to guide the maintenance of advanced non-small cell lung cancer.